Opinion

Video

Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

This episode discusses the impressive ORR of more than 40% from the phase 2 TROPION-Lung05 trial of Dato-DXd in patients with EGFR-mutated advanced NSCLC, its clinical impact on those treated with 3 or more prior therapies, and explores the potential of Dato-DXd as a practice-changing therapy, given the median DOR of 7 months and DCR of 79%.

Video content above is prompted by the following:

  • From the primary results of the phase 2 TROPION-Lung05 trial, please share your impressions of the ORR of greater than 40% among patients with EGFR-mutated advanced or metastatic NSCLC.
  • From a clinical practice perspective, how impactful is this response rate, particularly among patients who had received 3or more lines of prior therapy?
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.